# CBD is a Human Right — Influencer & Social Toolkit

**Campaign:** Care Before Discrimination — CBD is a Human Right  
**Use:** launch and post-launch sharing pack for coalition partners, patient advocates, clinicians, public-interest influencers and allied organisations  
**Version:** Final v2.1 · 17 June 2026  
**Core rule:** this is health-policy advocacy, not product promotion. Do not name, tag, link, compare, discount or recommend any CBD product, retailer or brand.

---

## 1. The one ask

**Sign and share the open appeal. Ask governments to decide CBD policy in the open, on published evidence, with patients consulted.**

The safest short version:

> **Care before discrimination. Decide CBD in the open, on the evidence. Sign and share the appeal.**

---

## 2. Message discipline: what this campaign is and is not

**This campaign is:**

- a patient-rights and transparency campaign;
- evidence-led, non-partisan and pro-regulation;
- focused on proportional rules: testing, labelling, age protections where relevant, market surveillance, and enforcement against intoxicating synthetic and semi-synthetic products;
- centred on patient autonomy, dignity and open decision-making.

**This campaign is not:**

- CBD product marketing;
- medical advice;
- a claim that CBD is harmless or treats every condition;
- a defence of unregulated markets;
- an attack on cannabis patients, hemp farmers, regulators, HHC sellers or any community.

**Tone:** calm, credible, human, firm. No stoner imagery, no panic language, no conspiracy framing.

---

## 3. Source-safe facts influencers may use

Use only these fact lines unless the coalition approves additional wording.

1. **Pure CBD is not internationally scheduled as a narcotic or psychotropic substance.**
2. **The INCB notice describes evidence of CBD as the actual starting material for THC or semi-synthetic cannabinoids as limited.**
3. **The documented Romanian HHC case appeared to obtain CBD on site from industrial hemp / low-THC cannabis, not from diverted patient or consumer CBD.**
4. **HHC has already been placed under international control as a psychotropic substance.**
5. **The EU Court of Justice has held that CBD restrictions cannot rest on purely hypothetical considerations.**
6. **The coalition is not asking for deregulation; it is asking for published evidence, proportionate regulation and patient consultation.**

For detailed sources, link people to: **https://www.cbdhumanright.org/evidence/**

---

## 4. Links

Use the petition link in the reader's language where possible.

| Language | Petition link |
|---|---|
| EN | https://www.openpetition.eu/petition/online/care-before-discrimination-is-a-human-right |
| CZ | https://www.openpetition.eu/petition/online/pece-pred-diskriminaci-prava-pacientu-a-navrhovane-omezeni-cbd |
| IT | https://www.openpetition.eu/petition/online/la-cura-prima-della-discriminazione-e-un-diritto-umano |
| FR | https://www.openpetition.eu/petition/online/le-soin-avant-la-discrimination-est-un-droit-humain |
| ES | https://www.openpetition.eu/petition/online/el-cuidado-antes-que-la-discriminacion-es-un-derecho-humano |
| DE | https://www.openpetition.eu/petition/online/fuersorge-vor-diskriminierung-ist-ein-menschenrecht |

Additional links:

- Website / sign hub: https://www.cbdhumanright.org/ and https://www.cbdhumanright.org/sign/
- Evidence brief and sources: https://www.cbdhumanright.org/evidence/
- Appeal and press materials: https://www.cbdhumanright.org/press/
- Short link for tight character counts: https://openpetition.eu/smylm

**Before sending:** verify every link, add tracking parameters if the web team is using them, and confirm the correct language link for each influencer.

---

## 5. Hashtags and tagging

Primary hashtags:

- #CBDisaHumanRight
- #CareBeforeDiscrimination

Czech hashtags:

- #PecePredDiskriminaci
- #CBDjeLidskePravo

Optional Czech diacritic versions where platform search supports them:

- #PéčePředDiskriminací
- #CBDjeLidskéPrávo

Coalition organisations to tag after handle verification:

- KOPAC — Patient Association for Cannabis Treatment (Czech Republic)
- Dosemociones (Spain)
- Aube (Canada)
- Verein Medcan (Switzerland)
- PatientsCann (United Kingdom)

**Do not use unverified handles.** Keep a shared handle sheet and update this toolkit only after confirmation.

---

## 6. Core message pillars

Pick one pillar per post. Do not overload a single post with every argument.

### Pillar 1 — Decide in the open

A decision affecting patients should not be made through a quiet administrative process. If governments want to restrict lawful CBD, they should publish the evidence, test proportionality and consult patients.

### Pillar 2 — Follow the evidence

Pure CBD is not internationally scheduled as a narcotic or psychotropic substance. The policy question is not whether CBD can be converted under deliberate laboratory conditions; it is whether lawful CBD channels are actually being diverted into illicit manufacture.

### Pillar 3 — Target the real risk

Intoxicating synthetic and semi-synthetic cannabinoids require enforcement. But many dangerous SCRA / "Spice" products are not made from CBD, and HHC is already controlled as an end-product. Act on harmful products directly; do not restrict patient access by default.

### Pillar 4 — Regulate, do not prohibit by stealth

The coalition supports testing, labelling, dose limits, age protections where relevant, contaminant controls and market surveillance. It opposes a blanket or covert precursor restriction without published evidence of actual diversion.

### Pillar 5 — Patients are not suspects

Patients deserve autonomy, dignity and evidence-based decisions. People who rely on lawful CBD should not be stigmatised as if they hold a drug precursor.

---

## 7. Ready-to-post copy

*The captions below use the EN short link `openpetition.eu/smylm`. For non-English audiences, swap in the reader's language link from §4.*

### X / Twitter — short launch post

> A quiet move to restrict CBD as a "drug precursor" could affect patients across Europe. The evidence should be published before access is restricted. Decide CBD in the open, on the evidence. Sign + share: https://openpetition.eu/smylm #CBDisaHumanRight

### X / Twitter — evidence line

> Pure CBD is not internationally scheduled as a narcotic or psychotropic substance. If governments want to restrict lawful access, they should publish evidence of actual diversion — not rely on hypotheticals. Sign: https://openpetition.eu/smylm #CareBeforeDiscrimination

### X / Twitter — HHC / synthetic cannabinoids line

> Synthetic and semi-synthetic cannabinoids need targeted enforcement. But a blanket CBD restriction is the wrong tool: many dangerous "Spice" products are not made from CBD, and HHC is already controlled. Protect patients. Sign: https://openpetition.eu/smylm

### X / Twitter — patient dignity line

> Patients are not suspects. They deserve autonomy, dignity and decisions made in daylight. Ask governments to publish the evidence before restricting lawful CBD access. Sign + share: https://openpetition.eu/smylm #CBDisaHumanRight

### LinkedIn / Facebook — professional post

> An international coalition of patient organisations has launched **Care Before Discrimination**, an open appeal on CBD, patient access and transparent decision-making.
>
> The concern is narrow but serious: lawful CBD may be restricted by treating it as a "drug precursor". The coalition is not asking for deregulation. It is asking for the opposite of a covert ban: publish the evidence, test proportionality, regulate product quality, act directly on intoxicating synthetic and semi-synthetic cannabinoids, and consult the patients affected.
>
> Pure CBD is not internationally scheduled as a narcotic or psychotropic substance. The INCB notice asks for vigilance and supply-chain knowledge, but it does not by itself prove large-scale diversion from lawful CBD channels. Under EU law, restrictions must be evidence-based, necessary and proportionate.
>
> Read the evidence and add your name: https://www.cbdhumanright.org/
>
> #CBDisaHumanRight #CareBeforeDiscrimination

### Instagram caption

> Care before discrimination.
>
> A quiet move to restrict CBD as a "drug precursor" could affect patients across Europe. Before lawful access is restricted, governments should publish the evidence, consult patients and use proportionate regulation — not a covert ban.
>
> Sign and share the appeal. Link in bio / petition link: https://openpetition.eu/smylm
>
> #CBDisaHumanRight #CareBeforeDiscrimination

### Instagram first comment

> Sign + share the open appeal: https://openpetition.eu/smylm  
> Evidence brief: https://www.cbdhumanright.org/evidence/

### WhatsApp / Telegram broadcast

> Care Before Discrimination: patients need your voice. A quiet move to restrict CBD as a "drug precursor" should not happen without published evidence and patient consultation. Please sign and forward: https://openpetition.eu/smylm

### Email / newsletter

**Subject options:**

1. Add your name: patients are being shut out of a CBD decision
2. Care Before Discrimination: decide CBD in the open
3. Evidence first, patients first: sign the CBD appeal

**Body:**

> Dear friends,
>
> An international patient coalition has launched **Care Before Discrimination**, an open appeal asking governments to decide CBD policy in the open, on published evidence, with patients consulted.
>
> The concern is not ordinary product regulation. The concern is a possible restriction of lawful CBD by treating it as a "drug precursor". The coalition supports proportionate regulation: testing, labelling, contaminant controls, age protections where relevant, and direct enforcement against intoxicating synthetic and semi-synthetic cannabinoids.
>
> What it opposes is a covert or blanket restriction before governments publish evidence that lawful CBD channels are actually being diverted into illicit manufacture.
>
> Read the evidence: https://www.cbdhumanright.org/evidence/
>
> Sign the appeal: https://www.cbdhumanright.org/sign/
>
> Please share this with anyone who cares about patient dignity, transparent decision-making and evidence-based policy.

---

## 8. Influencer outreach pack

### Short DM

> Hi [name] — we have launched **Care Before Discrimination**, a patient-coalition appeal asking governments to decide CBD policy in the open, on published evidence. It is not product promotion and not a call for deregulation: it asks for proportionate rules, action on harmful intoxicating products, and patient consultation. Would you share one post or story today? Link: https://openpetition.eu/smylm Thank you.

### Longer email

**Subject:** Could you share the Care Before Discrimination appeal today?

> Hi [name],
>
> We have launched **Care Before Discrimination**, a patient-coalition appeal connected to the **CBD is a Human Right** campaign.
>
> A quiet move to restrict lawful CBD as a "drug precursor" could affect patients across Europe. The appeal asks for a simple standard: publish the evidence, test proportionality, regulate product quality, act directly on intoxicating synthetic and semi-synthetic cannabinoids, and consult the patients affected.
>
> This is health-policy advocacy, not CBD product promotion. We are not asking for deregulation and we are not claiming CBD is harmless. We are asking that decisions affecting patients be made in the open, on evidence.
>
> Could you share one post or story today? Suggested captions and graphics are attached.
>
> Link: https://openpetition.eu/smylm
>
> Thank you for helping patients be heard.

### Follow-up message after 24 hours

> Hi [name] — just checking whether you might still be able to share the Care Before Discrimination appeal. Even one story helps send a signal that patient access decisions should be transparent and evidence-based. Link: https://openpetition.eu/smylm Thank you.

### Copy influencers can paste

**Short caption:**

> Patients deserve CBD decisions made in the open, on evidence — not by quiet administrative restriction. Sign the Care Before Discrimination appeal: https://openpetition.eu/smylm #CBDisaHumanRight

**Medium caption:**

> I am backing **Care Before Discrimination**, a patient-coalition appeal asking governments to publish the evidence before restricting lawful CBD access. This is not product promotion and not a call for deregulation. It is a call for transparency, proportionate regulation and patient dignity. Sign: https://openpetition.eu/smylm

**Story line:**

> CBD policy should be decided in daylight, on evidence. Sign the patient appeal: https://openpetition.eu/smylm

---

## 9. Comment replies and FAQ

Use these replies to keep comments accurate and calm.

**"Are you saying CBD is harmless?"**

> No. CBD has real safety and quality issues: interactions, dose questions, labelling problems and contamination risks. That is why we support testing, labelling, dose guidance and market surveillance. The point is that these risks support proportionate regulation, not a covert precursor restriction without evidence of diversion.

**"Are synthetic cannabinoids dangerous?"**

> Yes. Intoxicating synthetic and semi-synthetic cannabinoids need targeted enforcement. The issue is whether restricting lawful CBD is the right tool. We say act directly on the harmful products and unlawful manufacture, while protecting patients who rely on lawful, tested CBD.

**"Is CBD legal everywhere?"**

> No. Laws vary by country and product category. The campaign is not giving legal advice. The point is that pure CBD is not internationally scheduled as a narcotic or psychotropic substance, and any restriction affecting patient access should be evidence-based, transparent and proportionate.

**"Why call it a human right?"**

> The campaign is not claiming a free-standing legal right to any single product. "CBD is a Human Right" is a public campaign banner for Care Before Discrimination: patient autonomy, dignity, transparent decision-making and proportionate regulation.

**"Is this advertising CBD?"**

> No. This campaign does not promote, sell, recommend or link to any CBD product or brand. It is public-interest advocacy about evidence-based policy and patient access.

---

## 10. Moderation rules

Keep the conversation credible.

Hide, delete or report:

- product sales, discount codes or brand promotion;
- medical cure claims or dosing advice;
- abuse, threats, hate speech or harassment;
- misinformation that repeatedly ignores correction;
- comments encouraging illegal activity.

Respond once with facts. Do not argue endlessly. Redirect to the evidence page: https://www.cbdhumanright.org/evidence/

---

## 11. Asset-to-copy map

| Asset | Best use | Caption |
|---|---|---|
| `stories/story_01_sign_appeal` / `square_posts/sq_01_sign_appeal` | Launch ask | Add your name. Decide CBD in the open, on the evidence. |
| `story_02_incb_quote` / `sq_02_incb_quote` | Evidence frame | The regulator's own notice calls the precursor evidence limited. Publish the evidence before restricting access. |
| `story_03_real_patients` / `sq_03_real_patients` | Patient frame | Real patients. Real stakes. A ban does not remove demand; it shifts risk onto vulnerable people. |
| `story_04_kanavape` / `sq_04_kanavape` | Legal frame | The EU Court of Justice has already said restrictions cannot rest on purely hypothetical considerations. |
| `story_05_parent_child` | Family / dignity frame | Protect families with proportionate regulation, not covert prohibition. |
| `story_06_five_demands` / `sq_05_regulate_not_prohibit` | Coalition asks | Publish the evidence. No covert ban. Regulate — don't prohibit. Act on the real risk. Consult patients. |
| `story_07_who_safety` / `sq_07_who_safety` | CBD baseline | Pure CBD is not internationally scheduled as a narcotic or psychotropic substance. Policy should follow evidence. |
| `story_08_transparency` / `sq_08_transparency` | Trust frame | We hold ourselves to the standard we demand: transparency, evidence and patient dignity. |
| `story_09_coalition` / `sq_06_eu_parliament` | Coalition frame | An open patient coalition across countries. Add your name. |
| `carousel/` | Explainer accounts | What is happening -> what the evidence says -> why patients are affected -> what we ask -> sign today. |

---

## 12. Launch-day run of show

Use CET. Adjust if launch time changes.

| Time | Action | Owner |
|---|---|---|
| 08:30 | Final check: website live, petition links live, evidence page live, graphics downloadable, handles verified. | Web + comms |
| 09:00 | Publish launch post on coalition channels. Pin posts where possible. | Coalition orgs |
| 09:05 | Send partner WhatsApp / Telegram broadcast with language-specific petition links. | Country leads |
| 09:15 | Send influencer DM/email pack to priority list. | Influencer lead |
| 10:00 | Post first story sequence: what is happening + sign appeal. | Social lead |
| 11:30 | Reply to comments, collect screenshots of supportive posts, thank early signers. | Community lead |
| 13:00 | Publish LinkedIn / Facebook professional post for journalists, clinicians and policymakers. | Policy comms |
| 16:00 | Publish carousel explainer. Re-share top coalition and influencer posts. | Social lead |
| 18:00 | Post signature milestone or "thank you / keep sharing" update if available. | Social lead |
| Next morning | Follow up with influencers who have not posted; publish evidence-focused update. | Influencer lead |

---

## 13. Post-launch rhythm

For the week after launch:

- Day 1: launch ask + patient dignity
- Day 2: evidence / INCB "limited evidence" line
- Day 3: HHC and synthetic cannabinoids: target the real risk
- Day 4: legal/proportionality line
- Day 5: coalition and signatory milestone
- Day 6: patient voices and why consultation matters
- Day 7: recap and renewed signing push

Repeat the one ask in every post: **sign and share the appeal.**

---

## 14. Compliance and safety checklist

Before posting or sending to influencers, confirm:

- [ ] No CBD brand, product, retailer, dose recommendation or treatment claim appears.
- [ ] No unverified statistics, names, handles or quotes appear.
- [ ] The post links to the petition, website, evidence page or press page only.
- [ ] Any paid or materially supported influencer relationship is disclosed according to local law and platform rules.
- [ ] No health data or patient story is collected without explicit consent and a clear privacy notice.
- [ ] Paid promotion is not used unless legal, platform and issue-advertising compliance has been checked for the target country.
- [ ] The language version matches the audience.
- [ ] The post does not attack regulators, sellers, cannabis communities or individual officials.

---

## 15. Do / do not

**Do:**

- say "publish the evidence";
- say "decide in the open";
- say "regulate proportionately";
- say "act on the real risk";
- say "patients are not suspects";
- link to the evidence page when challenged.

**Do not:**

- claim CBD is harmless;
- claim CBD treats or cures conditions;
- claim CBD can never be converted under laboratory conditions;
- claim all synthetic cannabinoids are made from CBD;
- claim CBD is legal everywhere;
- attack HHC sellers or the cannabis community;
- promote any CBD product, brand or retailer;
- invent numbers, deadlines, officials or quotes.

---

## 16. Final campaign boilerplate

> **Care Before Discrimination — CBD is a Human Right** is an open patient-coalition appeal calling for transparent, evidence-based and proportionate decision-making on CBD. The coalition supports regulation of product quality and enforcement against intoxicating synthetic and semi-synthetic cannabinoids. It opposes a covert or blanket precursor-based restriction of lawful CBD unless governments publish evidence that such a measure is necessary, proportionate and protective of patients.

---

*Need new graphics or content? See the companion **Influencer Asset & Content Request List** (2026-06-17) for the full brief of new images, captions and short-video scripts to commission.*
